PRIMA cancer immunotherapy, PI Timofei Zatsepin

Cancer immunotherapy (Nobel Prize in Physiology and Medicine 2018) is a breakthrough technology that revolutionized the treatment of previously incurable cancers and significantly prolonged the lifetime of patients. Unfortunately for most of malignancies a typical response of patients to current checkpoint inhibitors in cancer immunotherapy does not exceed 25-40%. Our project is devoted to enhance response to checkpoint inhibitors.